|Bid||122.03 x 800|
|Ask||122.15 x 800|
|Day's Range||119.46 - 122.33|
|52 Week Range||55.90 - 123.02|
|Beta (5Y Monthly)||0.57|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 22, 2021 - Feb 26, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||128.89|
You hope that every single stock you buy goes up. Otherwise, you wouldn't buy the stocks in the first place. Predicting whether they'll actually appreciate in value and by how much is just guesswork.
Guardant Health, Inc. (Nasdaq: GH) today announced the pricing of its offering of $1,000,000,000 aggregate principal amount of 0% convertible senior notes due 2027 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The issuance and sale of the notes are scheduled to settle on November 19, 2020, subject to customary closing conditions. Guardant Health also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date notes are first issued, up to an additional $150,000,000 principal amount of notes.
Despite the roaring bull market on Monday, shares of cancer diagnostics specialist Guardant Health (NASDAQ: GH) fell dramatically. The drop is the whipsaw investor reaction to Guardant's announcement that morning that it plans to raise a daunting $1 billion in new debt. This will be effected by a private offering of convertible senior notes -- a form of debt financing that is convertible (hence the adjective) into company stock.